Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00017485 · ClinicalTrials.gov registry record · Phase 1
Photodynamic Therapy in Treating Patients With Basal Cell Skin Cancer
A Phase 1 study of Non-melanomatous Skin Cancer, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT00017485 is a Phase 1 study of Non-melanomatous Skin Cancer that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 6 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00017485, a Phase 1 study of Non-melanomatous Skin Cancer, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. Photosensitizing drugs such as HPPH are absorbed by cancer cells and, when exposed to light, become active and kill the cancer cells. PURPOSE: Phase I trial to study the effectiveness of photodynamic therapy with HPPH in treating patients who have basal cell skin cancer.
Conditions Studied
Interventions
- DRUG HPPH
Study Locations (1)
New York
- Roswell Park Cancer Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2000-01 |
| Est. Completion | 2007-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00017485
The ClinicalTrials.gov registry entry for NCT00017485 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-melanomatous Skin Cancer appearing as the primary indexed condition, and to 1 intervention - of which HPPH is the first listed.
NCT00017485 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00017485 about?
NCT00017485 is a clinical study titled "Photodynamic Therapy in Treating Patients With Basal Cell Skin Cancer". RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. Photosensitizing drugs such as HPPH are absorbed by cancer cells and, when exposed to light, become active and kill the cancer cells. PURPOSE: Phase I trial to study the effectiv...
What is the current status of trial NCT00017485?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2000-01. Estimated completion is 2007-01.
What conditions does trial NCT00017485 study?
This clinical trial studies the following conditions: Non-melanomatous Skin Cancer.
What interventions are being tested in trial NCT00017485?
The interventions under investigation include: HPPH (DRUG).
Who is sponsoring clinical trial NCT00017485?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00017485 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-melanomatous Skin Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.